Analyst Viewpoint
Rise in prevalence of HPV-related diseases is driving the global market. Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) across the world. Campaigns and initiatives by governments for the development and distribution of HPV vaccines to control the spread of HPV is another major factor propelling market expansion. Furthermore, increase in initiatives by governments is expected to bolster the global human papillomavirus vaccine market size during the forecast period.
Development of novel molecules targeting HPV offers lucrative opportunities to market players. Manufacturers are investing significantly in the development of new HPV vaccines for all age groups in order to increase market share.
Human papillomavirus, also known as HPV, is a common virus that affects various parts of the body. HPV is a group of more than 200 related viruses, of which more than 40 strains are spread through direct sexual contact. HPV that affects genitals is generally a sexually transmitted infection (STI) which is passed via physical contacts.
Among these, two HPV strains cause genital warts, and about a dozen HPV types can cause certain types of cancer such as cervical, anal, oropharyngeal, penile, vulvar, and vaginal. Generally, the body can find and clear out HPV, but in some cases the virus stays in the body for a long period of time, which can cause cancer.
HPV vaccines stimulate the body to produce antibodies that, in future encounters with HPV, bind to the virus and prevent it from infecting cells. The vaccine simply protects the body from getting any type of cancer caused due to HPV. As a result, getting vaccinated against HPV helps prevent cancer in both men and women.
According to human papillomavirus vaccine market research, governments across the world are introducing several campaigns and initiatives for the development and distribution of HPV vaccines to control the spread of human papillomavirus.
Private organizations and government bodies are funding screening and immunization programs and distribution of HPV vaccines across various parts of the world. In January 2023, an article published in Vaccines Journal stated that the HPV vaccine is fully funded for children aged 11 years to 14 years and for 15- to 26-year-old females in Switzerland.
In January 2021, the United States Department of Health and Human Services launched the "HPV VAX NOW" campaign to increase HPV vaccination rates among young adults aged 18-26 years.
Global organizations, such as UNICEF, have made attempts to improve vaccine acceptance over the years. The Pan American Health Organization’s (PAHO) revolving fund and UNICEF supply division allows vaccinations to be procured at lower prices for various countries. PAHO and UNICEF purchase vaccines for roughly 40 states and around 100 countries each year, boosting the adoption rate of viral infection vaccine.
HPV is the most common sexually transmitted infection (STI) in the world. Around 80% of all sexually active people are estimated to be infected by HPV at some point in their lives. Increase in cases of HPV-related diseases such as cervical cancer, anal cancer, vaginal cancer and others is expected to bolster the global human papillomavirus vaccine market demand during the forecast period.
According to HPV and Related Cancers report 2023, cervical cancer ranks as the 2nd most frequent cancer among women in India, and the 2nd most frequent cancer among women between 15 and 44. As per the same source, 123,907 women are diagnosed with cervical cancer in India each year.
North America accounted for the largest global human papillomavirus vaccine market share in 2022. This is ascribed to improved healthcare infrastructure and increase in cases of cervical cancer and other HPV-related cancers among the population.
A report published in 2022 by the American Cancer Society stated that 9,440 new anal cancers were diagnosed in the U.S. in the same year. Moreover, as per the Canadian Cancer Society, 1,450 Canadian women were diagnosed with cervical cancer in 2022.
According to an article published in February 2023 in the Human Vaccine and Immunotherapeutic Journal, HPV vaccination in the U.S. can start at age nine and last until age 26. Approximately 77% of teenagers 13 to 17 years old have received one or more doses of the HPV vaccine, and nearly 62% have finished the entire series. Significant coverage for HPV vaccine and early screening initiatives are expected to propel the human papillomavirus vaccine market growth in the region.
Major players are focusing on product launches and investment in research & development to increase the effectiveness of the human papillomavirus vaccine in adults. These companies are following the latest human papillomavirus vaccine market trends to avail lucrative revenue opportunities.
Merck & Co., Inc., GlaxoSmithKline plc, Sanofi, AstraZeneca, Serum Institute of India Pvt. Ltd., Xiame Innovax Biotech CO., LTD., General Incorporated Foundation, The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), and Bharat Biotechare are the prominent players in the global human papillomavirus vaccine market.
Each of these companies has been profiled in the human papillomavirus vaccine market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 4.0 Bn |
| Forecast (Value) in 2031 | US$ 9.1 Bn |
| Growth Rate (CAGR) | 9.4% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 4.0 Bn in 2022
It is anticipated to grow at a CAGR of 9.4% from 2023 to 2031
Increase in initiatives by governments and rise in prevalence of HPV-related diseases
The quadrivalent and nonavalent segment accounted for the largest share in 2022
North America was the leading region in 2022
Merck & Co., Inc., GlaxoSmithKline plc., Sanofi, AstraZeneca, Serum Institute of India Pvt. Ltd., Xiame Innovax Biotech CO., LTD., General Incorporated Foundation, The Chemo-Sero-Therapeutic Research Institute (Kaketsuken), and Bharat Biotech.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Human Papillomavirus Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Valence, 2017–2031
6.3.1. Bivalent
6.3.2. Quadrivalent and Nonavalent
6.4. Market Attractiveness Analysis, by Valence
7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Cervical Cancer
7.3.2. Anal Cancer
7.3.3. Vaginal Cancer
7.3.4. Penile Cancer
7.3.5. Vulvar Cancer
7.3.6. Oropharyngeal Cancer
7.3.7. Genital Warts
7.3.8. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Physicians
8.3.2. Wholesalers
8.3.3. Physician Distributors
8.3.4. Government Entities
8.3.5. Public and Private Alliances
8.4. Market Attractiveness Analysis, by Indication
9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Human Papillomavirus Vaccine Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Valence, 2017–2031
10.3.1. Bivalent
10.3.2. Quadrivalent and Nonavalent
10.4. Market Value Forecast, by Indication, 2017–2031
10.4.1. Cervical Cancer
10.4.2. Anal Cancer
10.4.3. Vaginal Cancer
10.4.4. Penile Cancer
10.4.5. Vulvar Cancer
10.4.6. Oropharyngeal Cancer
10.4.7. Genital Warts
10.4.8. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Physicians
10.5.2. Wholesalers
10.5.3. Physician Distributors
10.5.4. Government Entities
10.5.5. Public and Private Alliances
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Valence
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Valence, 2017–2031
11.3.1. Bivalent
11.3.2. Quadrivalent and Nonavalent
11.4. Market Value Forecast, by Indication, 2017–2031
11.4.1. Cervical Cancer
11.4.2. Anal Cancer
11.4.3. Vaginal Cancer
11.4.4. Penile Cancer
11.4.5. Vulvar Cancer
11.4.6. Oropharyngeal Cancer
11.4.7. Genital Warts
11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Physicians
11.5.2. Wholesalers
11.5.3. Physician Distributors
11.5.4. Government Entities
11.5.5. Public and Private Alliances
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Valence
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Valence, 2017–2031
12.3.1. Bivalent
12.3.2. Quadrivalent and Nonavalent
12.4. Market Value Forecast, by Indication, 2017–2031
12.4.1. Cervical Cancer
12.4.2. Anal Cancer
12.4.3. Vaginal Cancer
12.4.4. Penile Cancer
12.4.5. Vulvar Cancer
12.4.6. Oropharyngeal Cancer
12.4.7. Genital Warts
12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Physicians
12.5.2. Wholesalers
12.5.3. Physician Distributors
12.5.4. Government Entities
12.5.5. Public and Private Alliances
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Valence
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Valence, 2017–2031
13.3.1. Bivalent
13.3.2. Quadrivalent and Nonavalent
13.4. Market Value Forecast, by Indication, 2017–2031
13.4.1. Cervical Cancer
13.4.2. Anal Cancer
13.4.3. Vaginal Cancer
13.4.4. Penile Cancer
13.4.5. Vulvar Cancer
13.4.6. Oropharyngeal Cancer
13.4.7. Genital Warts
13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Physicians
13.5.2. Wholesalers
13.5.3. Physician Distributors
13.5.4. Government Entities
13.5.5. Public and Private Alliances
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Valence
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Valence, 2017–2031
14.3.1. Bivalent
14.3.2. Quadrivalent and Nonavalent
14.4. Market Value Forecast, by Indication, 2017–2031
14.4.1. Cervical Cancer
14.4.2. Anal Cancer
14.4.3. Vaginal Cancer
14.4.4. Penile Cancer
14.4.5. Vulvar Cancer
14.4.6. Oropharyngeal Cancer
14.4.7. Genital Warts
14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Physicians
14.5.2. Wholesalers
14.5.3. Physician Distributors
14.5.4. Government Entities
14.5.5. Public and Private Alliances
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Valence
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Merck & Co., Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. GlaxoSmithKline plc
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Sanofi
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. AstraZeneca
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Serum Institute of India Pvt. Ltd.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Xiame Innovax Biotech Co., Ltd.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. General Incorporated Foundation
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Bharat Biotechare
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031
Table 02: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031
Table 07: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031
Table 11: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031
Table 15: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031
Table 19: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017–2031
Table 23: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
Figure 02: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Valence, 2022
Figure 03: Global Human Papillomavirus Vaccine Market Value Share, by Valence, 2022
Figure 04: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Human Papillomavirus Vaccine Market Value Share, by Indication, 2022
Figure 06: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Human Papillomavirus Vaccine Market Value Share, by Distribution Channel, 2022
Figure 08: Global Human Papillomavirus Vaccine Market Value Share, by Region, 2022
Figure 09: Global Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 11: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 12: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 13: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 15: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Region, 2017 and 2031
Figure 17: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Country, 2017 and 2031
Figure 21: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 22: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 23: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 24: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031
Figure 25: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031
Figure 26: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 30: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 31: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 32: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 33: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031
Figure 34: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031
Figure 35: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 39: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 40: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 41: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 42: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031
Figure 43: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031
Figure 44: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 48: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 49: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 50: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 51: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031
Figure 52: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023–2031
Figure 53: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 57: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 58: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 59: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 60: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023–2031
Figure 61: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2022–2031
Figure 62: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Human Papillomavirus Vaccine Market
